Trial Profile

A Phase I Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lodapolimab (Primary) ; Prexasertib (Primary)
Indications Carcinoma; Colorectal cancer; Leiomyosarcoma; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Uterine cancer
Focus Adverse reactions

Most Recent Events

01 Oct 2021 Results assessing the immune modulating effect and safely in combination at the RP2D of CHK1 inhibition with prexasertib in combination with LY3300054, published in the Cancer Immunology Immunotherapy.
09 Feb 2021 Status changed from active, no longer recruiting to completed.
03 Feb 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com